Healthcare resource utilization and costs of cardiovascular events in patients with atherosclerotic cardiovascular disease in Germany – results of a claims database study

References

• Deutsche Herzstiftung e.V. Deutscher Herzbericht 2019. 2019.
   Google Scholar
• März W, Dippel F-W, Theobald K, et al. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: real-world evidence from Germany. Atherosclerosis. 2018;268:99–107.
   PubMed Web of Science ®Google Scholar
• Lechner K, von Schacky C, McKenzie AL, et al. Lifestyle factors and high-risk atherosclerosis: pathways and mechanisms beyond traditional risk factors. Eur J Prev Cardiol. 2020;27(4):394–406.
   PubMed Web of Science ®Google Scholar
• Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension. 2020;75(2):285–292.
   PubMed Web of Science ®Google Scholar
• Lacruz ME, Kluttig A, Hartwig S, et al. Prevalence and incidence of hypertension in the general adult population. Medicine. 2015;94(22):e952.
   PubMed Web of Science ®Google Scholar
• Gatwood J, Bailey JE. Improving medication adherence in hypercholesterolemia: challenges and solutions. Vasc Health Risk Manag. 2014;10:615–625.
   PubMedGoogle Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188.
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722.
   PubMed Web of Science ®Google Scholar
• Chapman RH, Liu LZ, Girase PG, et al. Determining initial and follow-up costs of cardiovascular events in a US managed care population. BMC Cardiovasc Disord. 2011;11:11.
   PubMed Web of Science ®Google Scholar
• Tarride J-E, Lim M, DesMeules M, et al. A review of the cost of cardiovascular disease. Can J Cardio. 2009;25(6):195–202.
   Google Scholar
• Statistisches Bundesamt DESTATIS. Herz-Kreislauf-Erkrankungen verursachen die höchsten Kosten. 2017; [cited 2021 Feb 04]. Available from: https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Gesundheit/Krankheitskosten/_inhalt.html#sprg232688.
   Google Scholar
• Dornstauder E, Sidelnikov E, Minartz C, et al. Burden of Disease and Social IMPACT of Myocardial Infarction and Ischemic Stroke in Germany from 2018 until 2030. ISPOR Europe 2020. 2020.
   Google Scholar
• Akobeng AK. Assessing the validity of clinical trials. J Pediatr Gastroenterol Nutr. 2008;47(3):277–282.
   PubMed Web of Science ®Google Scholar
• Andersohn F, Walker J. Characteristics and external validity of the German Health Risk Institute (HRI) database. Pharmacoepidemiol Drug Saf. 2016;25(1):106–109.
   PubMed Web of Science ®Google Scholar
• Bundesministerium für Gesundheit. Kennzahlen der Gesetzlichen Krankenversicherung 2007 bis. 2018. Kennzahlen und Faustformeln. Available from: https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/5_Publikationen/Gesundheit/Broschueren/KF2019Bund_Maerz_2019.pdf.
   Google Scholar
• Statistisches Bundesamt DESTATIS. Ergebnisse der Bevölkerungsfortschreibung auf Grundlage des Zensus. 2011. Available from: https://www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/Bevoelkerung/Bevoelkerungsstand/Tabellen/Zensus_Geschlecht_Staatsangehoerigkeit.html.
   Google Scholar
• Bundesministerium der Justiz und für Verbraucherschutz. § 287 SGB V. Available from: https://www.gesetze-im-internet.de/sgb_5/__287.html.
   Google Scholar
• Bundesministerium der Justiz und für Verbraucherschutz. § 75 SGB X. Available from: https://www.gesetze-im-internet.de/sgb_10/__75.html.
   Google Scholar
• Deutschen Institut für Medizinische Dokumentation und Information. ICD-10-GM Version 2020 Systematisches Verzeichnis. 2019.
   Google Scholar
• Stahmeyer JT, Stubenrauch S, Geyer S, et al. The frequency and timing of recurrent stroke. Dtsch Arztebl Int. 2019;116(42):711–717.
   PubMed Web of Science ®Google Scholar
• Khanevski AN, Bjerkreim AT, Novotny V, et al. Recurrent ischemic stroke: incidence, predictors, and impact on mortality. Acta Neurol Scand. 2019;140(1):3–8.
   PubMed Web of Science ®Google Scholar
• Nakatani D, Sakata Y, Suna S, et al. Incidence, predictors, and subsequent mortality risk of recurrent myocardial infarction in patients following discharge for acute myocardial infarction. Circ J. 2013;77(2):439–446.
   PubMed Web of Science ®Google Scholar
• Breuckmann F, Hochadel M, Darius H, et al. Guideline-adherence and perspectives in the acute management of unstable angina – initial results from the German chest pain unit registry. J Cardiol. 2015;66(2):108–113.
   PubMed Web of Science ®Google Scholar
• Gitt A, Rieber J, Hambrecht R, et al. Do acute coronary events affect lipid management and cholesterol goal attainment in Germany? Results from the dyslipidemia international study II. Wien Klin Wochenschr. 2018;130(23–24):707–715.
   PubMed Web of Science ®Google Scholar
• Huang Q, Grabner M, Sanchez R, et al. Clinical characteristics and unmet need Among patients with atherosclerotic cardiovascular disease stratified by statin use. Am Health Drug Benefits. 2016;9(8):434–444.
   PubMedGoogle Scholar
• Waßmuth S, Rohe K, Noack F, et al. Adherence to lipid-lowering therapy in patients with coronary heart disease From The state Of Saxony-Anhalt, Germany. Vasc Health Risk Manag. 2019;15:477–483.
   PubMed Web of Science ®Google Scholar
• Schmid T. Costs of treating cardiovascular events in Germany: a systematic literature review. Health Econ Rev. 2015;5(1):27.
   PubMedGoogle Scholar
• Reinhold T, Lindig C, Willich SN, et al. The costs of myocardial infarction – a longitudinal analysis using data from a large German health insurance company. J Public Health. 2011;19(6):579–586.
   Google Scholar
• GKV Spitzenverband. GKV-Kennzahlen. Available from: https://www.gkv-spitzenverband.de/service/zahlen_und_grafiken/gkv_kennzahlen/gkv_kennzahlen.jsp.
   Google Scholar
• Davis KL, Meyers J, Zhao Z, et al. High-risk atherosclerotic cardiovascular disease in a real-world employed Japanese population, cardiovascular event rates, and costs. J Atheroscler Thromb. 2015;22(12):1287–1304.
   PubMed Web of Science ®Google Scholar
• Kirsch F, Becker C, Schramm A, et al. Effects of continuous enrollment in a structured disease management program in patients with coronary artery disease after acute myocardial infarction on adherence to guideline recommended medication, health care expenditures, and survival. Eur J Health Econ. 2020;21(4):607–619.
   PubMed Web of Science ®Google Scholar